登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients
ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由北京协和医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07553793,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed locally unresectable or abdominopelvic metastatic pancreatic ductal adenocarcinoma.
入选标准第 5 条
Received the following anti-tumor treatments prior to apheresis: Immunomodulatory therapy within 7 days; Cytotoxic therapy within 14 days; Investigational medication, targeted therapy, or anti-tumor traditional Chinese medicine within 28 days.
排除标准第 1 条
Previous anti-tumor therapy-related Adverse Events (AEs) that have not resolved to Grade 1.
排除标准第 17 条
ECOG performance status of 0-1.
入选标准第 4 条
At least one measurable lesion according to RECIST v1.1 criteria.
入选标准第 8 条
Females of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first dose and must not be lactating.
入选标准第 11 条
Pregnant or lactating women; women or men of childbearing potential planning pregnancy during the study period.
排除标准第 21 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07553793,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Able to understand and voluntarily sign a written informed consent form. Willing and able to comply with the scheduled visit and treatment plan, laboratory tests, and other study requirements. Aged ≥ 18 years and ≤ 75 years on the day of signing the informed consent form, male or female. ECOG performance status of 0-1. Histologically or cytologically confirmed locally unresectable or abdominopelvic metastatic pancreatic ductal adenocarcinoma. Pancreatic cancer patients who have failed at least one prior line of therapy or are intolerant to such therapy. Medium to high expression of C-MET in pancreatic cancer tissue (defined as ++ or higher, with positive cells > 25%). At least one measurable lesion according to RECIST v1.1 criteria. Expected survival ≥ 4 months. Adequate organ function as defined by the following laboratory requirements: Females of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first dose and must not be lactating.排除标准:Exclusion Criteria:
Received the following anti-tumor treatments prior to apheresis: Immunomodulatory therapy within 7 days; Cytotoxic therapy within 14 days; Investigational medication, targeted therapy, or anti-tumor traditional Chinese medicine within 28 days. Previously received CAR-T cell therapy or other cell therapies targeting any antigen. Liver metastases occupying more than 30% of the total liver volume. History of other concurrent malignancies, except for the following: Completely resected or eradicated basal cell carcinoma and squamous cell carcinoma of the skin, cervical carcinoma in situ, minute/microscopic papillary thyroid carcinoma, minute/microscopic breast cancer, and other malignancies with an extremely low risk of recurrence or metastasis. Patients with a history of autoimmune disease requiring immunosuppressive medication or hormone therapy (excluding physiological replacement doses). History of severe Central Nervous System (CNS) disease, such as grand mal seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or psychosis. Patients with a left ventricular ejection fraction (LVEF) < 50%, severe structural cardiac abnormalities, or arrhythmias requiring medical treatment. Patients with a history of medical treatment for intestinal obstruction, or those with imaging findings during screening indicating intestinal obstruction requiring treatment. Moderate to severe hepatic steatosis (fatty liver). Patients with moderate to severe cirrhosis (Child-Pugh Class A or worse) and significant portal hypertension. Patients with a history of gastrointestinal bleeding within the past 6 months requiring blood transfusion, emergency room observation, or hospitalization. Patients with active peptic ulcers. Patients with a history of severe intra-abdominal infection. History of abdominal surgery within the past 3 months. Any uncontrolled active infection. Infectious diseases, including but not limited to: 1) Known Human Immunodeficiency Virus (HIV) infection or Acquired Immunodeficiency Syndrome (AIDS)-related illness; 2) Hepatitis B (HBsAg positive) or Hepatitis C (HCV RNA positive); 3) Active tuberculosis infection, or currently receiving anti-tuberculosis therapy, or having received anti-tuberculosis therapy within 1 year prior to the first dose of study drug; 4) Positive for Treponema pallidum antibody; 5) Other infectious diseases deemed unsuitable for participation in this study by the investigator. Previous anti-tumor therapy-related Adverse Events (AEs) that have not resolved to Grade 1. Patients with deep vein thrombosis (DVT) or other conditions requiring anticoagulation therapy (e.g., heparin, warfarin). Patients with a history of any arterial embolism. Presence of other serious conditions prior to apheresis that could potentially limit the subject's participation in this trial, such as: Poorly controlled diabetes (glycated hemoglobin [HbA1c] > 8% despite treatment), inadequately controlled hypertension (blood pressure > 160 mmHg / 100 mmHg despite medication), myocardial infarction within the last 6 months, severe arrhythmia or unstable angina not well controlled by medication, pulmonary embolism, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), etc. Pregnant or lactating women; women or men of childbearing potential planning pregnancy during the study period. Substance abuse (medication or drugs), or clinical, psychological, or social factors that would impair informed consent or study conduct. Patients with a history of severe allergies (e.g., allergies to three or more substances including food, drugs, etc.). Presence of moderate or severe ascites. Currently participating in another interventional clinical trial. Any uncertainty that could affect patient safety or compliance. Any other condition deemed by the investigator to make the subject unsuitable for enrollment.
引自 ClinicalTrials.gov, NCT07553793, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07553793,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。